

**Alcidion Group Limited (ABN 77 143 142 410)****Appendix 4E - Preliminary Final Report for the year ended 30 June 2021  
as required by ASX listing rule 4.3A****Results for announcement to the market****Reporting Periods**

<b>Current reporting period</b>	<b>1 July 2020 to 30 June 2021</b>
Previous reporting period	1 July 2019 to 30 June 2020

**Results for announcement to the market**

		<b>\$000</b>
Revenue from ordinary activities	Up 39% to	25,882
Loss from ordinary activities after tax attributable to members	Up 27% to	(2,244)
Loss for the period attributable to members	Up 27% to	(2,244)

**Dividends**

No dividends were paid or proposed for the current or previous corresponding period.

**Explanation of results**

Additional information supporting the Appendix 4E disclosure requirements can be found in the Annual Report which contains the Director's Report and the 30 June 2021 Financial Statements and accompanying notes.

**Net tangible assets per security**

	<b>30 June 2021</b>	<b>30 June 2020</b>
Net tangible assets per security	\$0.017	\$0.012

**Details of entities over which control has been gained or lost during the period**

On 14 April 2021 100% of the shares of ExtraMed Limited were acquired by the Group.  
Extramед Limited is a company registered in England and Wales.

This report is based on the consolidated financial statements for the year ended 30 June 2021 which have been audited by William Buck. The Audit report is not subject to a modified opinion or emphasis of matter.